Molecular Imaging Clinical Trial
Official title:
Targeted Molecular Imaging of [68Ga]- Labelling Anti-EGFR Affibody Molecule in EGFR ECD in Lung Cancer Patients and Healthy Volunteers
The investigators developed [68Ga]-labelling Anti-EGFR Affibody Molecule as a targeted molecular imaging agent for noninvasive and repeatable detecting EGFR-ECD expression status.
The goals of investigators are to evaluate the use of [68Ga]-labelling Anti-EGFR Affibody Molecule as a novel PET/CT radiotracer to monitor EGFR-ECD expression status and classify EGFR-ECD benefit NSCLC patients. The investigators want to evaluated the use of [68Ga]-labelling Anti-EGFR Affibody Molecule in lung cancer imaging in adult NSCLC patients with different EGFR-ECD expression status of primary and metastatic cancers. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01944215 -
Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue
|
Phase 1 | |
| Recruiting |
NCT02916394 -
In Vivo IGF-1R Molecular Imaging Using [68Ga]- Labelling Anti-IGF-1R Affibody Molecule
|
N/A | |
| Active, not recruiting |
NCT03358589 -
Molecular Evaluation in Metastatic Breast Cancer
|
N/A | |
| Completed |
NCT03031522 -
EGFR Molecular Classification In Vivo
|
N/A | |
| Recruiting |
NCT02717221 -
In Vivo EGFR Molecular Classification and Treatment Response
|
N/A | |
| Completed |
NCT03233243 -
Rosuvastatin Effect on Atherosclerotic Plaque Metabolism
|
Phase 4 | |
| Completed |
NCT02323217 -
I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers
|
Early Phase 1 | |
| Enrolling by invitation |
NCT05575765 -
Clinical Validation of Multimodal Digestive Endoscopy
|